Skip to main content

Drug Interactions between encorafenib and glasdegib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

encorafenib glasdegib

Applies to: encorafenib and glasdegib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of glasdegib, which is primarily metabolised by CYP450 3A4 and to a lesser extent CYP450 2C8 and UGT1A9. When glasdegib was coadministered with rifampin, a potent CYP450 3A4 inducer, glasdegib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 35% and 70%, respectively, compared to administration of glasdegib alone. Reduced efficacy of glasdegib may occur. In addition, when two or more medications with similar adverse effect profiles are given concurrently, the likelihood of experiencing these adverse reactions may be increased. For example, coadministration with other agents that can prolong the QT interval (e.g., apalutamide, encorafenib, enzalutamide) may result in additive effects and an increased risk of ventricular arrhythmias like torsade de pointes.

MANAGEMENT: Concomitant use of glasdegib with potent CYP450 3A4 inducers should generally be avoided.

References

  1. (2023) "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group
  2. (2022) "Product Information. Daurismo (glasdegib)." Pfizer Ltd
  3. (2022) "Product Information. Daurismo (glasdegib)." Pfizer Canada ULC

Drug and food interactions

Major

encorafenib food

Applies to: encorafenib

You should preferably avoid consumption of grapefruit and grapefruit juice while taking encorafenib. Grapefruit and grapefruit juice can significantly increase the blood levels of encorafenib. This may increase the risk of serious side effects such as bleeding complications, eye and vision problems, liver problems, irregular heart rhythm, and development of new skin cancers. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

glasdegib food

Applies to: glasdegib

Grapefruit and grapefruit juice may increase the blood levels and effects of glasdegib. This can increase the risk of serious side effects such as an irregular heart rhythm, inflammation and ulceration of the digestive tract, low red or white blood cells, fever, low platelet levels, bleeding, and swelling. You should avoid consumption of grapefruit and grapefruit juice during treatment with glasdegib. Otherwise, you may need a dose adjustment and/or more frequent monitoring by your doctor to safely use this medication. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer